B-cell lymphoma is driven by genetic changes, but the vast majority of those changes are acquired during a person’s lifetime rather than inherited from a parent. Having a first-degree relative (parent, sibling, or child) with non-Hodgkin lymphoma raises your risk by about 1.7-fold, which is a modest increase from a relatively low baseline. So while family history plays a role, B-cell lymphoma is not a straightforwardly “genetic” disease in the way conditions like sickle cell anemia or cystic fibrosis are.
Inherited vs. Acquired Genetic Changes
There are two distinct ways genetics factor into B-cell lymphoma. The first is inherited (germline) mutations, the DNA you’re born with. The second is acquired (somatic) mutations, errors that accumulate in your B cells over the course of your life due to aging, environmental exposures, chronic inflammation, or simple bad luck during cell division. Nearly all B-cell lymphomas are driven primarily by somatic mutations.
That said, inherited mutations are more common in lymphoma patients than previously thought. In one study of 22 patients with diffuse large B-cell lymphoma (DLBCL), the most common subtype, 20 carried rare inherited variants in DNA repair genes, averaging two variants per person. About 27% of DLBCL patients in another analysis carried inherited mutations in mismatch repair genes, which are responsible for catching and fixing errors when DNA copies itself. And roughly 6% of DLBCL patients carry inherited mutations in a gene called CHEK2, which normally acts as a checkpoint to stop damaged cells from multiplying.
Researchers have now identified inherited mutations in over one-third of the same genes that are found to be mutated in DLBCL tumors. This doesn’t mean those inherited mutations directly cause lymphoma, but they may create a vulnerability, a weaker defense system that makes it easier for additional acquired mutations to push a B cell toward cancer.
How Family History Affects Your Risk
The largest study on this topic pooled more than 17,000 non-Hodgkin lymphoma cases and 23,000 controls from 20 studies worldwide. It found that having a first-degree relative with non-Hodgkin lymphoma raises your own risk by 1.8 times. A separate cohort study of over 120,000 women found a similar number: 1.7 times the risk for B-cell non-Hodgkin lymphoma specifically.
To put that in perspective, non-Hodgkin lymphoma affects roughly 2% of people over a lifetime. A 1.7-fold increase brings that to about 3.4%, which is still a low absolute risk. For comparison, the familial risk for chronic lymphocytic leukemia (a related B-cell cancer) is much steeper at 8.5-fold, and Hodgkin lymphoma sits at about 3.1-fold. So among blood cancers, B-cell non-Hodgkin lymphoma has one of the more modest hereditary components.
The Genetic Mutations That Drive Lymphoma
The mutations that actually transform a normal B cell into a lymphoma cell are almost always somatic. They tend to involve chromosomal translocations, where a piece of one chromosome breaks off and attaches to another, landing a growth-promoting gene next to a segment of DNA that keeps it permanently switched on.
The key players in B-cell lymphoma include three genes. MYC (on chromosome 8) drives rapid cell growth. BCL2 (on chromosome 18) blocks the normal self-destruct process that clears out damaged cells. BCL6 (on chromosome 3) keeps cells locked in an immature, rapidly dividing state. BCL2 translocations appear in 20 to 30% of DLBCL cases and in the vast majority of follicular lymphomas. When a tumor acquires translocations in both MYC and BCL2 (or BCL6), it’s classified as a “double-hit” lymphoma, which accounts for 7 to 10% of DLBCL cases and behaves more aggressively, with median survival historically ranging from 4.5 to 18.5 months.
These translocations aren’t inherited. They occur during the normal life cycle of B cells, which naturally rearrange their DNA to produce diverse antibodies. That rearrangement process occasionally goes wrong, and over decades the errors can accumulate.
Epigenetic Changes Add Another Layer
Beyond mutations that alter the DNA sequence itself, B-cell lymphomas frequently involve epigenetic changes: modifications that don’t rewrite the genetic code but change which genes get turned on or off. Think of it as the difference between changing the words in a book and highlighting or crossing out entire pages.
These changes are especially common in DLBCL and follicular lymphoma. About 30% of DLBCL cases and up to 90% of follicular lymphoma cases carry mutations in a gene called KMT2D, which normally helps activate tumor-suppressing genes. When KMT2D stops working, B cells expand unchecked and lose their ability to mature properly. Another 40% of DLBCL and follicular lymphoma cases have mutations in genes (CREBBP and EP300) that normally help activate a key tumor suppressor and deactivate an oncogene called BCL6. When these controls fail, the cell becomes more tolerant of DNA damage and less likely to self-destruct.
These epigenetic mutations are also somatic, not inherited. But they help explain why lymphoma develops even in people with no family history and no obvious inherited risk.
Rare Inherited Syndromes Linked to B-Cell Lymphoma
A small number of inherited conditions do carry a direct risk. One example is BENTA disease, caused by an inherited mutation in a gene called CARD11. People with this condition are born with abnormally expanding B cells, enlarged lymph nodes, and an enlarged spleen, and some go on to develop B-cell malignancies. Notably, the exact same CARD11 mutation found in BENTA disease also shows up as a somatic mutation in DLBCL tumors, illustrating how the same genetic error can arise by inheritance or by chance.
Inherited mutations in the ETV6 gene cause a syndrome of low platelet counts and predisposition to several cancers, including blood cancers. And inherited mutations in mismatch repair genes like MSH2, best known for raising the risk of colon cancer, have been found in at least one case of follicular lymphoma. These syndromes are rare, but they confirm that inherited genetics can, in uncommon situations, set the stage for B-cell lymphoma.
How Genetic Testing Fits Into Diagnosis
When someone is diagnosed with B-cell lymphoma, genetic testing of the tumor itself is standard practice. The most common technique is called FISH (fluorescence in situ hybridization), which uses fluorescent probes to detect specific chromosomal translocations like MYC, BCL2, and BCL6 rearrangements. Identifying these rearrangements matters because it changes the diagnosis: a lymphoma with both MYC and BCL2 rearrangements is classified differently and treated more aggressively than one without.
What’s less established is routine genetic screening for healthy family members of lymphoma patients. Unlike hereditary breast cancer, where BRCA testing is well-defined and actionable, there is no standard panel of genes recommended for lymphoma family screening. The 1.7-fold familial risk increase, while real, doesn’t yet translate into clear surveillance protocols the way a BRCA mutation leads to mammogram schedules. If lymphoma runs in your family, the most practical step is making sure your doctors know your family history so they can factor it into any evaluation of unexplained symptoms like persistent swollen lymph nodes, unexplained weight loss, or drenching night sweats.